Our laboratory has focused its research in the area of ovarian cancer and drug resistance. Ovarian cancer is unique in that newly diagnosed disease is almost uniformly sensitive to chemotherapy yet nearly all patients will eventually succumb to resistant disease. Our focus has been primarily directed at transcriptional and post transcriptional regulation.
David R. Spriggs, MD
Research FocusPhysician-scientist David Spriggs studies the molecular mechanisms of drug resistance in ovarian cancer.
EducationMD, University of Wisconsin, Madison
- C. Aghajanian, D.S. Dizon, P. Sabbatini, J.J. Raizer, J. Dupont, and D.R. Spriggs. A Phase I Trial of Bortezomib and Carboplatin in Recurrent Ovarian or Primary Peritoneal Cancer. J Clin Oncol. 2005 Sep 1;23(25):5943-9.
- Aliza L. Leiser, Guangli Yang, Huasong Tian, Gregory Springett, Magdalena Dabrowska, Xiu Jun Yan, Nestor Rosales, William Bornmann, David R. Spriggs. Novel Tetrafluorodinated Phthalimide Analogues with ’are’ Dependent TNF-ALPHA Regulatory Activity. [In Press]